CStone Pharma Taps Arrotex to Commercialize Sugemalimab in Australia, New Zealand
MT Newswires Live
Jun 26
CStone Pharmaceuticals (HKG:2616) signed an exclusive commercialization agreement with Australia's Arrotex Pharmaceuticals for its cancer immunotherapy sugemalimab in Australia and New Zealand, according to a Thursday Hong Kong bourse filing.
The pharma company will receive an upfront payment, potential regulatory and commercial milestone payments, and a profit share on sales.
Arrotex will hold exclusive commercialization rights for sugemalimab across all approved and future indications in the two markets, subject to regulatory approval, and will oversee regulatory filings and commercialization.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.